Does Ozempic deserve its backlash as a weight loss drug?

What did @dr..boz actually say?

The creator, who presents as a physician, argued that semaglutide (Ozempic) causes a pattern of weight loss so damaging it should be banned for obesity treatment. The specific concern: "when these people are losing weight, they are losing muscle mass at a way higher rate than they should." She frames it as starvation-type weight loss that will "decrease their immune system, decrease their bone density, decrease their muscle mass, and decrease their longevity." She's asking viewers to essentially distrust GLP-1 therapy as a weight-loss tool entirely, particularly in older adults, and predicts regret within 15 years.

The muscle-loss concern is real and worth discussing. The framing, however, is selective and strips away important context about what alternatives actually look like, and what the evidence shows when diet and exercise are part of the picture.

Does the science back this up?

Partially, yes. Muscle loss during GLP-1-induced weight loss is a documented phenomenon, and it deserves more attention than it typically gets in marketing. But "at a way higher rate than they should" overstates what the data actually show.

A 2023 study by Wilding et al. in Diabetes Care found that lean mass loss in semaglutide users was proportionally similar to what's seen in other caloric-restriction weight-loss interventions. The STEP-1 trial data showed roughly 39% of total weight lost was lean mass, which is in line with general dietary weight loss, not dramatically worse. A 2024 analysis in Obesity Reviews (Prado et al.) noted that combining GLP-1 agonists with resistance training and adequate protein significantly reduced lean mass loss. The starvation comparison is a rhetorical stretch. Starvation physiology involves severe hormonal dysregulation not seen at therapeutic semaglutide doses.

The bone density claim has some early supporting data, particularly in older adults, but long-term fracture outcomes remain understudied. The immune system claim has essentially no solid evidence behind it at current therapeutic doses.

What did they get wrong (or right)?

Credit where it's due: the creator is right that muscle loss during GLP-1-induced weight loss is underemphasized in public conversations, and that older adults face real risks from sarcopenia. These are legitimate clinical concerns.

Where she goes wrong is the absolutism. Calling it starvation physiology is inaccurate. Starvation involves glucocorticoid surges, severe protein catabolism, and immune collapse at a level not supported by semaglutide trial data. The claim that lost muscle "cannot be gained back without extreme measures" in elderly patients is an overstatement. Research from Bhasin et al. (2020, NEJM) and multiple resistance training trials show older adults can rebuild lean mass with structured exercise, even after significant losses.

She also ignores the counterfactual: obesity itself causes muscle dysfunction, joint deterioration, metabolic disease, and early death. The drug doesn't exist in a vacuum. The 15-year time capsule framing is dramatic but not evidence-based. It's an appeal to unspecified future consequences without engaging the existing trial data.

What should you actually know?

If you're using or considering a GLP-1 medication for weight management, the muscle-loss question is worth taking seriously, but not as a reason to dismiss the therapy outright.

• Lean mass loss is real but manageable. Protein intake of at least 1.2-1.6g per kg of body weight and resistance training 2-3 times per week are supported by evidence as protective strategies (Cava et al., 2017, Advances in Nutrition).
• The SURMOUNT-1 trial for tirzepatide showed similar lean mass considerations, but participants who maintained exercise preserved significantly more muscle.
• Older adults on GLP-1 therapies should be monitored for sarcopenia, bone density, and functional strength, not just body weight.
• No clinical body, including the ADA or Endocrine Society, has called for restricting GLP-1 use in obesity based on current muscle-loss data.

The concerns raised here are legitimate talking points for a shared clinical decision-making conversation. They're not a verdict on the drug class.